Vimachem

Vimachem is a pharmaceutical software company specializing in IIoT-enabled Pharma 4.0 AI-driven manufacturing execution systems (MES) for life sciences operations. Founded in 2006 with dual headquarters in New York and Athens, Vimachem delivers a modular, intelligent platform designed exclusively for pharmaceutical and biopharmaceutical manufacturing, addressing the digital transformation needs of regulated production environments.

The company's flagship Pharma MES Platform integrates Electronic Batch Records (eBR), Weigh & Dispense Module (WDM), Serialization Site Manager (SSM), Digital Work Instructions, Machine Data Connectivity, Manufacturing Analytics & OEE, and Digital Pharma Forms & Logbooks into a unified cloud-based SaaS solution. The platform is deployed across 200+ pharmaceutical manufacturing sites globally, serving customers including Aspen Pharma (Australia), Elpen, Athenex, IBERFAR, and MEDICE Arzneimittel.

Vimachem positions itself as a Pharma 4.0 innovator, emphasizing rapid deployment timelines, built-in FDA 21 CFR Part 11 compliance, and IoT integration capabilities enabling connectivity to manufacturing equipment. The company is privately funded with backing from Endeavor Greece and is preparing for a fundraising round. Employee satisfaction on Glassdoor is 4.7/5 across 19 reviews, with 96% of employees recommending the company to friends.

Vimachem is a pharma-exclusive vendor, operating entirely within the pharmaceutical and biopharmaceutical manufacturing sector. Its IIoT Pharma MES Platform is purpose-built for life sciences operations, with no diversification into other industries. The platform is deployed across 200+ pharmaceutical manufacturing sites globally.

Named pharma customers include Aspen Pharma (Australia), Elpen, Athenex, IBERFAR (Indústria Farmacêutica S.A.), and MEDICE Arzneimittel Pütter GmbH & Co. KG. Aspen Pharma pairs Vimachem SSM for site-level serialization with Wipotec OCS line-level units. Elpen integrated six packaging lines without production disruption. Athenex required minimal training for platform adoption. IBERFAR uses the platform across its engineering and information systems teams. MEDICE Arzneimittel selected Vimachem's Level 3 Serialization Site Manager for plant-level serialization. The customer base spans Big Pharma, mid-size pharmaceutical manufacturers, and specialty biotech companies across multiple geographies including Australia, Europe, and North America.

Vimachem markets built-in FDA 21 CFR Part 11 compliance and publishes compliance articles and guidelines on its website. It is deployed in highly regulated GMP manufacturing environments. The company markets rapid deployment with full compliance from initial rollout.

Vimachem is privately funded, with undisclosed revenue. Endeavor Greece has invested in the company; per Crunchbase (2025), no institutional VC funding round has closed. It has created a data room and an investor shortlist in preparation for a funding round.

Vimachem has operated continuously since 2006, with its platform deployed across 200+ pharmaceutical sites globally. Recent hiring includes a CSV & Implementation Consultant with 7 years of experience, onboarded in 2025, and active talent acquisition efforts. Its Glassdoor rating is 4.7/5, with 96% of employees recommending the company to friends.

Vimachem's product portfolio centers on the Vimachem Pharma MES Platform, a modular IIoT-enabled Pharma 4.0 AI-driven manufacturing execution system. The flagship platform integrates seven core modules: Electronic Batch Records (eBR) for automated batch record management with 21 CFR Part 11 compliance; Weigh & Dispense Module (WDM) for automated material weighing and dispensing with barcode validation; Serialization Site Manager (SSM) for Level 3 serialization and aggregation management; Digital Work Instructions providing interactive step-by-step operator guidance; Machine Data Connectivity enabling IIoT integration with manufacturing equipment; Manufacturing Analytics & OEE delivering real-time dashboards for product quality and cycle time visibility; and Digital Pharma Forms & Logbooks replacing paper-based documentation.

The company employs a modular approach allowing customers to implement individual modules independently or as an integrated suite, enabling phased rollouts starting with high-priority capabilities (typically eBR or serialization) and expanding over time.

The platform includes AI-driven analytics for real-time process monitoring and decision support, IoT integration enabling automated data capture from scales, barcode scanners, sensors, and production equipment, and no-code configurability allowing organizations to customize workflows without extensive IT intervention. The cloud-based SaaS delivery model eliminates on-premise infrastructure requirements and provides automatic updates and enhancements.

Vimachem references technology partnerships on its website. No partnership with a major cloud provider (AWS, Azure, Google) or ERP vendor (SAP, Oracle) is named.

The company provides implementation and consulting services directly, including MES deployment, digital transformation consulting, and computerized system validation (CSV) support. It participated in FutureLink 2025. Vimachem maintains a dedicated partners page on its website (www.vimachem.com/resources/partners/), though the page does not name any partners.

Integration capabilities include RESTful APIs for connectivity with ERP systems, LIMS, and other enterprise applications, enabling data exchange with existing IT infrastructure. The modular platform architecture supports phased integration, allowing customers to connect Vimachem modules with legacy systems gradually.

Vimachem provides professional services spanning MES implementation, digital transformation consulting, and computerized system validation (CSV) support. Customer testimonials cite Elpen integrating six packaging lines without production disruption and Athenex requiring minimal training.

G2 reviews cite inadequate support during night shifts, leaving technical assistance unavailable during off-peak hours. Undisclosed: support availability, regional coverage, multilingual support, and SLA (Service Level Agreement) details.

Professional services include implementation support for platform deployment, validation assistance for FDA/GMP compliance documentation, training for operators and quality personnel, and ongoing technical support. The company offers annual support packages for modules such as the Level 3 Serialization Site Manager following installation and qualification. Undisclosed: user community programs, certification offerings, customer conferences, and formal user forums.

Vimachem's customer base includes multinational pharmaceutical companies Aspen Pharma (Australia) and MEDICE Arzneimittel (Germany), across 200+ global pharmaceutical site deployments. No ISO 9001, ISO 27001, or SOC 2 certification is claimed.

Leadership and founder details are undisclosed on the public website. The company has published a compliance article, "21 CFR Part 11 Compliance: Guidelines & Checklist For Pharma." Recent news coverage includes a "Welcome New Team Members" announcement and participation in FutureLink 2025.

Vimachem's Glassdoor rating is 4.7/5 across 19 anonymous reviews, with 96% of employees recommending the company to friends. No Gartner, Forrester, or other analyst recognition is claimed.

Vimachem's website features product information, customer testimonials, compliance resources, and news updates. The company publishes educational content including compliance guidelines, case studies, and product tours (an eBR Product Tour is available online), and offers a request-a-demo option. Its resources section includes testimonials, case studies, news, partners, and articles.

Vimachem maintains LinkedIn and YouTube channels, referenced in the website footer; LinkedIn carries recruitment posts and company updates. Recent 2025 news includes team-member announcements and participation in FutureLink 2025.

Vimachem markets itself as the "first IIoT-enabled Pharma 4.0 AI manufacturing platform," targeting pharmaceutical manufacturers moving off legacy MES systems.